Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) has been given a $19.00 price target by equities research analysts at Royal Bank Of Canada in a report issued on Monday. The brokerage currently has a “sector perform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price objective points to a potential upside of 40.24% from the company’s previous close.

Several other research analysts also recently weighed in on VRX. Canaccord Genuity set a $19.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Wednesday, February 22nd. Wells Fargo & Company restated an “underperform” rating and issued a $11.50 target price on shares of Valeant Pharmaceuticals International in a research note on Thursday, February 23rd. Rodman & Renshaw restated a “neutral” rating and issued a $17.00 target price (down from $23.00) on shares of Valeant Pharmaceuticals International in a research note on Monday, February 27th. HC Wainwright set a $23.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Tuesday, February 28th. Finally, Guggenheim restated a “buy” rating and issued a $55.00 target price on shares of Valeant Pharmaceuticals International in a research note on Tuesday, February 28th. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $16.26.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Valeant Pharmaceuticals International (VRX) traded up 6.00% during midday trading on Monday, hitting $13.42. 22,374,391 shares of the stock were exchanged. The firm has a 50 day moving average of $12.26 and a 200 day moving average of $12.99. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $32.74. The firm’s market cap is $4.67 billion. Valeant Pharmaceuticals International also was the target of some unusual options trading activity on Friday. Investors acquired 35,088 put options on the stock. This represents an increase of 215% compared to the average daily volume of 11,124 put options.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.93. The business had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $2.17 billion. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. The business’s quarterly revenue was down 11.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.08) earnings per share. Equities analysts forecast that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/06/19/royal-bank-of-canada-analysts-give-valeant-pharmaceuticals-international-inc-vrx-a-19-00-price-target.html.

In other news, Director Schutter Richard U. De acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, May 11th. The shares were acquired at an average price of $13.90 per share, with a total value of $278,000.00. Following the acquisition, the director now directly owns 70,572 shares in the company, valued at $980,950.80. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.87% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in VRX. Cambridge Advisors Inc. boosted its stake in Valeant Pharmaceuticals International by 0.6% in the first quarter. Cambridge Advisors Inc. now owns 12,650 shares of the specialty pharmaceutical company’s stock worth $140,000 after buying an additional 75 shares during the period. World Asset Management Inc boosted its stake in Valeant Pharmaceuticals International by 1.5% in the first quarter. World Asset Management Inc now owns 21,502 shares of the specialty pharmaceutical company’s stock worth $237,000 after buying an additional 328 shares during the period. Janney Montgomery Scott LLC boosted its stake in Valeant Pharmaceuticals International by 4.5% in the first quarter. Janney Montgomery Scott LLC now owns 19,573 shares of the specialty pharmaceutical company’s stock worth $216,000 after buying an additional 848 shares during the period. Gulf International Bank UK Ltd boosted its stake in Valeant Pharmaceuticals International by 1.1% in the first quarter. Gulf International Bank UK Ltd now owns 98,323 shares of the specialty pharmaceutical company’s stock worth $1,084,000 after buying an additional 1,100 shares during the period. Finally, Warren Averett Asset Management LLC boosted its stake in Valeant Pharmaceuticals International by 14.0% in the first quarter. Warren Averett Asset Management LLC now owns 11,402 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 1,402 shares during the period. 50.45% of the stock is currently owned by institutional investors and hedge funds.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.